Alterity Therapeutics Secures FDA Agreement on Pivotal Phase 3 ATH434 Trial in Multiple System Atrophy
On June 9, 2026, Alterity Therapeutics (NASDAQ: ATHE) announced that it had successfully concluded an End-of-Phase 2 meeting with the U.S. FDA, securing complete alignment on the design and key components of its pivotal Phase 3 program for ATH434 in Multiple System Atrophy (MSA).
MSA is a rare, rapidly progressive, and devastating neurodegenerative disorder characterized by autonomic nervous system failure and severe movement impairment. There are currently no approved disease-modifying therapies.
FDA Alignment on Phase 3 Study Design
The FDA agreed on all major registrational elements of the proposed Phase 3 study, establishing a clear pathway toward a potential New Drug Application (NDA) submission. The finalized parameters include:
- Study Population: Patients with early-stage MSA.
- Dosing Regimen: 50 mg twice daily (BID). This dose was selected after Phase 2 clinical data demonstrated a clinically meaningful 48% slowing of disease progression compared to placebo.
- Primary Endpoint: The Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, which is a clinician-rated scale consisting of 11 items measuring daily living activities and overall functional status.
- Secondary Endpoints and Statistical Methods: The FDA accepted the proposed secondary endpoints, which include the Clinical Global Impression of Severity and assessments of autonomic symptoms like orthostatic hypotension.
Fast Track and Orphan Drug Status
ATH434 is an oral small molecule designed to redistribute excess brain iron and inhibit the abnormal aggregation of alpha-synuclein, a key protein associated with neurodegeneration in MSA. The investigational drug has already been granted Fast Track and Orphan Drug designations by the FDA, as well as Orphan Drug designation by the European Medicines Agency (EMA).
With the Phase 3 design fully aligned with the FDA, Alterity Therapeutics plans to initiate clinical trial activities by the end of 2026, positioning ATH434 as a leading candidate in the race to deliver the first disease-modifying treatment for MSA.